Lipid and Atherosclerosis Forum
Identifying and Addressing Unmet Clinical Needs
Monday, 4th December 2023
(Day 1)
This meeting is for health care professionals and it is not open for members of the public. | ||
The meeting has been fully organised by the UK Lipid and Atherosclerosis Forum team/Manchester University Hospitals NHS Foundation Trust and endorsed by HEART UK. Amarin, Amgen, Amryt, Daiichi-Sankyo, Novartis, LINC Medial and Ultragenyx have sponsored the event and have had no input or influence into the agenda, content, or selection of speakers of this meeting. | ||
12:00 | Registration and Lunch | |
13:20 | Opening and welcome | Professor Handrean Soran |
SESSION 1 | Chairpersons: Prof Anne-Marie Kelly and Dr Ahai Luvai | |
13:30 | Data from France's HoFH register. | Professor Eric Buckert |
13:50 | Lp(a) in atherosclerosis and familial hypercholesterolaemia. | Professor Paul Durrington |
14:10 | Lipoprotein (a) as a therapeutic target: Current and future options. | Professor Ioanna Gouni-Berthold |
14:30 | International challenges for cardiovascular disease prevention. | Professor David Wood |
14:50 | Q&A | |
15:10 | Coffee | |
15:40 | SESSION 2 | Chairpersons: Dr Moulinath Banerjee and Dr Timothy Morris |
15:45 | Managing patients with HoFH: Current therapies. | Dr Michael France |
16:05 | Recommendation from the latest EAS HoFH statement and the role of new therapies. | Professor Eric Buckert |
16:25 | Familial Hypercholestrolaemia: Do we have a robust national plan? | Professor Anthony Wierzbicki |
16:45 | Nutraceuticals role in lipid lowering therapy: A review of efficacy and evidence. | Dr Peter Penson |
17:05 | Q&A | |
17:25 | Close Day 1 | |
18:15 | Speakers and Chairpersons meeting in the Lobby | |
18:30 | Transport to the Restaurant | |
19:00 | Speakers and Chairpersons Dinner | |
10:00 | Transport back to the hotel | |
Sponsors: Amarin, Amgen, Amryt, Daiichi-Sankyo, Novartis, LINC Medial and Ultragenyx . |
Tuesday, 5th December 2023
(Day 2)
This meeting is for health care professionals and it is not open for members of the public. | ||
The meeting has been fully organised by the UK Lipid and Atherosclerosis Forum team/Manchester University Hospitals NHS Foundation Trust and endorsed by HEART UK. Amarin, Amgen, Amryt, Daiichi-Sankyo, Novartis, LINC Medial and Ultragenyx have sponsored the event and have had no input or influence into the agenda, content, or selection of speakers of this meeting. | ||
0830 | Registration and coffee | |
0850 | Welcome | Professor Handrean Soran |
09:00 | SESSION 3 | Chairs: Dr Peter Elton and Dr Maryam Ferdousi |
09:05 | Hypertension: An update on recent clinical guidelines and therapeutic options. | Professor Anthony Heagerty |
09:30 | Obesity and insulin resistance as cardiometabolic risk factors. | Dr Jan Ho |
09:50 | Impact of Bariatric surgery on lipoproteins quality and functional obesity. | Dr Safwaan Adam |
10:10 | New medical therapies for weight reduction and their impact on cardiometabolic risk in patients with diabesity. | Professor Akheel Syed |
10:30 | Managing ASCVD risk in patients with type 1 diabetes. | Dr Jonathan Scofield |
10:50 | Q&A | |
11:10 | Coffee | |
11:40 | Session 4 | Chairs: Dr Ian Menown and Dr Naresh Kanumilli |
11:45 | Disrupting the care of cardiovascular disease with single-course gene editing medicines. | Dr Scott Vafai. |
12:05 | Current and future lipid modification therapy targets. | Professor Paul Durrington |
12:25 | From high-intensity statins to high-intensity lipid-lowering therapy. | Professor Lluis Masana |
12:45 | An overview of omega 3 fatty acids and their role in clinical practice. | Professor Gabriel Steg |
13:05 | Inflammation and Cardiovascular disease. An update on clinical trials. | Professor Peter Libby |
13:25 | Q&A | |
13:45 | Lunch | |
14:30 | Session 5 | Chairs: Dr Hannah Delaney and Dr Charlotte Dawson |
14:35 | Natural history of FCS and unmet clinical needs: Data from UK FCS register. | Dr Paul Downie |
15:00 | MAFLD/NAFLD and ASCVD: Lessons from Human Genetics. | Professor Stefano Romeo |
15:20 | Demystifying genetics of severe hypertriglyceridaemia. | Professor Robert Hegele |
15:40 | Current and future therapies for Severe Hypertriglyceridemia and FCS. | Professor Handrean Soran |
16:00 | TBC | TBC |
16:20 | Q&A | |
16:40 | Final remarks and close | Professor Handrean Soran |
Sponsors: Amarin, Amgen, Amryt, Daiichi-Sankyo, Novartis, LINC Medial and Ultragenyx. |